Alumis Inc.
- ALMS
- NASDAQ
- Biotechnology
- Autoimmune Therapies
- TYK2 Inhibitor
$6.12
Today −3.01%Quote Oct 16, 2026, 08:00 PM UTC
−21.74%over the last month
Max drawdown −25.3%From 1-month high −24.5%3 months −78.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$792.1M
Quote Oct 16
Next earnings
Nov 12
Expected, not confirmed
Analyst target
$29.57
+383.2% from here
Floor
$6.07
0.8% below price
Where the price sits
8 analysts
Analyst range, low to high
$15.00$40.00
- Price $6.12
- Resistance $6.34
- Consensus $29.57
The price is just above its floor. Analysts' average target sits about 383% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ALMSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
237
Founded
2021